Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 β5i)/LMP2 (β1i) β 1i) dual inhibitor

被引:1
|
作者
Arai, Yuuki [1 ]
Shitama, Hiroaki [1 ]
Yamagishi, Masahito [1 ]
Ono, Satoshi [1 ]
Kashima, Akiko [1 ]
Hiraizumi, Masahiro [1 ]
Tsuda, Naoki [1 ]
Katayama, Koushirou [1 ]
Tanaka, Kouji [1 ]
Koda, Yuzo [1 ]
Kato, Sayuka [1 ]
Sakata, Kei [1 ]
Nureki, Osamu [1 ,2 ]
Miyazaki, Hiroshi [1 ]
机构
[1] Mitsubishi Tanabe Pharm Corp, Sohyaku Innovat Res Div, 1000 Kamoshida cho,Aoba Ku, Yokohama 2270033, Japan
[2] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, 7-3-1 Hongo,Bunkyo ku, Tokyo 1130033, Japan
关键词
Immunoproteasome; LMP7; LMP2; Constitutive proteasome; beta; 5c; Cryo-EM; Autoimmune disease; PROTEASOME; BORTEZOMIB; MODEL;
D O I
10.1016/j.bmc.2024.117790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The immunoproteasome subunit LMP7 (beta 5i)/LMP2 (beta 1i) dual blockade has been reported to suppress B cell differentiation and activation, suggesting that the dual inhibition of LMP7/LMP2 is a promising approach for treating autoimmune diseases. In contrast, the inhibition of the constitutive proteasome subunit beta 5c correlates with cytotoxicity against non-immune cells. Therefore, LMP7/LMP2 dual inhibitors with high selectivity over beta 5c may be desirable for treating autoimmune diseases. In this study, we present the optimization and discovery of alpha-amido boronic acids using cryo-electron microscopy (cryo-EM). The exploitation of structural differences between the proteasome subunits led to the identification of a highly selective LMP7/LMP2 dual inhibitor 19. Molecular dynamics simulation based on cryo-EM structures of the proteasome subunits complexed with 19 explained the inhibitory activity profile. In mice immunized with 4-hydroxy-3-nitrophenylacetyl conjugated to ovalbumin, results indicate that 19 is orally bioavailable and shows promise as potential treatment for autoimmune diseases.
引用
收藏
页数:12
相关论文
共 4 条
  • [1] Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (β1i), MECL1 (β2i) and LMP7 (β5i)
    Scheffler, S.
    Kuckelkorn, U.
    Egerer, K.
    Doerner, T.
    Reiter, K.
    Soza, A.
    Burmester, G. -R.
    Feist, E.
    RHEUMATOLOGY, 2008, 47 (05) : 622 - 626
  • [2] Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
    Klein, Markus
    Busch, Michael
    Friese-Hamim, Manja
    Crosignani, Stefano
    Fuchss, Thomas
    Musil, Djordje
    Rohdich, Felix
    Sanderson, Michael P.
    Seenisamy, Jeyaprakashnarayanan
    Walter-Bausch, Gina
    Zanelli, Ugo
    Hewitt, Philip
    Esdar, Christina
    Schadt, Oliver
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (14) : 10230 - 10245
  • [3] Deficiency of the immunoproteasome subunit β5i/LMP7 supports the anxiogenic effects of mild stress and facilitates cued fear memory in mice
    Gorny, Xenia
    Saering, Paula
    Acosta, Jorge R. Bergado
    Kahl, Evelyn
    Kolodziejczyk, Malgorzata H.
    Cammann, Clemens
    Wernecke, Kerstin E. A.
    Mayer, Dana
    Landgraf, Peter
    Seifert, Ulrike
    Dieterich, Daniela C.
    Fendt, Markus
    BRAIN BEHAVIOR AND IMMUNITY, 2019, 80 : 35 - 43
  • [4] The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma
    Narukawa, Tsukasa
    Yasuda, Shusuke
    Horinaka, Mano
    Taniguchi, Keiko
    Tsujikawa, Takahiro
    Morita, Mie
    Ukimura, Osamu
    Sakai, Toshiyuki
    CANCERS, 2024, 16 (23)